ENTA’s HCV partnership with ABBV is certainly not an impediment to an ENTA buyout by another company. Neither ABBV nor ENTA will participate in further HCV clinical development, so the ABBV-ENTA partnership is now strictly a matter of royalty payments.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.